UnitedHealth faces DOJ fraud probe over Medicare Advantage billing practices, leading to stock plunge and broader healthcare sector impact.
FDA ends shortage of Ozempic and Wegovy, but compounding pharmacies must stop producing unapproved versions, potentially impacting patients who relied on more affordable options.
Federal judge halts Trump's executive orders targeting diversity, equity, and inclusion programs, citing concerns over free speech and arbitrary enforcement.
UnitedHealth faces DOJ fraud probe over Medicare Advantage billing practices, leading to stock plunge and broader healthcare sector impact.
FDA ends shortage of Ozempic and Wegovy, but compounding pharmacies must stop producing unapproved versions, potentially impacting patients who relied on more affordable options.
Federal judge halts Trump's executive orders targeting diversity, equity, and inclusion programs, citing concerns over free speech and arbitrary enforcement.